<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02445430</url>
  </required_header>
  <id_info>
    <org_study_id>15BN031</org_study_id>
    <nct_id>NCT02445430</nct_id>
  </id_info>
  <brief_title>Genetics of Arteriovenous Malformations</brief_title>
  <official_title>Genetics of Arteriovenous Malformations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Joseph's Hospital and Medical Center, Phoenix</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Translational Genomics Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Joe Niekro Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Joseph's Hospital and Medical Center, Phoenix</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to identify genetic alterations resulting in the development of&#xD;
      arteriovenous malformation (AVM) in the central nervous system.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will include AVM patients and members of their nuclear family. All patients will&#xD;
      donate a sample of saliva (5 mL) or blood (10 mL). Basic demographic and clinical parameters&#xD;
      will be collected, including ethnicity, age at first presentation, symptoms at presentation,&#xD;
      history of subsequent symptoms, treatment history, Spetzler-Martin AVM grade, medication&#xD;
      history, and other pertinent medical information. In patients undergoing AVM resection, a&#xD;
      small sample of the AVM will be collected for concurrent genomic analysis. Family members&#xD;
      will donate saliva (5mL) and document their relationship to the patient (i.e., parent,&#xD;
      sibling, child, etcl). Nucleic acids will be isolated from the saliva/blood samples, and&#xD;
      genetic sequencing will be carried out. When a surgical sample of the AVM is available,&#xD;
      nucleic acids will be obtained and transcriptome profiling will be performed. Identification&#xD;
      of genetic alterations common to patients with AVM and not present in samples from parents&#xD;
      and siblings will greatly aid in identification of pathways associated with AVM formation.&#xD;
      Candidate sequences will be chosen by differential expression (p&lt;0.05) and fold-changes. Once&#xD;
      identified, mechanisms for the rapid detection of marker sequences will be developed and&#xD;
      their predictive value tested in future collections.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 2015</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Family-Based</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Identification of genetic alterations common to patients with AVM</measure>
    <time_frame>sample analysis will take an expected average of six weeks</time_frame>
  </primary_outcome>
  <enrollment type="Actual">59</enrollment>
  <condition>Arteriovenous Malformation</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Saliva, blood, tissue (if undergoing AVM resection)&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Male and female persons with AVM and their immediate family members&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age between 6 and 60 years inclusive&#xD;
&#xD;
          -  Diagnosis of AVM or nuclear family member of a patient with AVM&#xD;
&#xD;
          -  Grants access to saliva, blood, and/or tissue&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age less than 6 years or greater than 61 years&#xD;
&#xD;
          -  Nuclear family members who do not share the same parents as the AVM patient&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph Zabramski, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Barrow Neurosurgical Associates</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Barrow Neurological Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 11, 2015</study_first_submitted>
  <study_first_submitted_qc>May 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2015</study_first_posted>
  <last_update_submitted>September 20, 2021</last_update_submitted>
  <last_update_submitted_qc>September 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>St. Joseph's Hospital and Medical Center, Phoenix</investigator_affiliation>
    <investigator_full_name>Lisa Arnold</investigator_full_name>
    <investigator_title>Research Manager</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemangioma</mesh_term>
    <mesh_term>Arteriovenous Malformations</mesh_term>
    <mesh_term>Congenital Abnormalities</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

